TABLE 2.
Demographic and patient characteristics at baseline.
| Characteristics |
Immunotherapy (N = 58) |
Chemotherapy combined immunotherapy(N = 32) |
Chemotherapy (N = 27) |
||||||
|---|---|---|---|---|---|---|---|---|---|
|
R (N = 27) |
NR (N = 31) |
Fisher.p |
R (n = 11) |
NR (n = 21) |
Fisher.p |
R (N = 13) |
NR (N = 14) |
Fisher.p | |
| Age | |||||||||
| Median(range)‐yr | 59 (31–80) | 58 (27–81) | 63 (49–74) | 63 (27–72) | 62 (51–77) | 60.5 (46–71) | |||
| ≥65 yr‐no. (%) | 12 (44) | 10 (32) | .4199 | 4 (36) | 10 (48) | .712 | 5 (38) | 4 (29) | .6946 |
| <65 yr‐no. (%) | 15 (56) | 21 (68) | 7 (64) | 11 (52) | 8 (62) | 10 (71) | |||
| Sex | |||||||||
| Male‐no (%) | 17 (63) | 23 (74) | .4041 | 9 (82) | 18 (86) | 1 | 12 (92) | 11 (79) | .5956 |
| Female‐no (%) | 10 (37) | 8 (26) | 2 (18) | 3 (14) | 1 (8) | 3 (21) | |||
| ECOG performance‐status score‐no (%) | |||||||||
| 0 | 12 (44) | 14 (45) | 1 | 6 (55) | 5 (24) | .1228 | 1 (8) | 4 (29) | .3259 |
| 1 | 15 (56) | 17 (55) | 5 (45) | 16 (76) | 12 (92) | 10 (71) | |||
| Primary location at diagnosis‐no (%) | |||||||||
| Gastroesophageal junction | 9 (33) | 7 (23) | .3929 | 1 (9) | 9 (43) | .1058 | 7 (54) | 4 (29) | .2519 |
| Stomach | 18 (67) | 24 (77) | 10 (91) | 12 (57) | 6 (46) | 10 (71) | |||
| Histologic subtype‐no. (%) | |||||||||
| Diffuse | 6 (22) | 13 (42) | .4168 | 3 (27) | 1 (5) | .211 | 0 | 1 (7) | .1962 |
| Intestinal | 12 (44) | 9 (29) | 5 (46) | 10 (48) | 7 (54) | 11 (79) | |||
| Mixed | 7 (26) | 7 (23) | 3 (27) | 6 (28) | 5 (38) | 2 (14) | |||
| Unknown | 2 (8) | 2 (6) | 0 | 4 (19) | 1 (8) | 0 | |||
| Previous gastrectomy no. (%) | |||||||||
| Yes | 11 (41) | 13 (42) | 1 | 1 (9) | 4 (19) | .6367 | 5 (38) | 4 (29) | .6946 |
| No | 16 (59) | 18 (58) | 10 (91) | 17 (81) | 8 (62) | 10 (71) | |||
| TNM staging | |||||||||
| III | 2 (7) | 1 (3) | .5931 | 0 | 1 (5) | 1 | 0 | 0 | 1 |
| IV | 25 (93) | 30 (97) | 11 (100) | 20 (95) | 13 (100) | 14 (100) | |||
| PD‐L1 combined positive score‐no. (%) | |||||||||
| ≥5 | 13 (48) | 8 (26) | .1353 | 4 (33) | 4 (19) | .3932 | 5 (38) | 3 (21) | .4989 |
| <5 | 6 (22) | 6 (19) | 3 (25) | 8 (38) | 5 (38) | 5 (36) | |||
| NA | 8 (30) | 17 (55) | 5 (42) | 9 (43) | 3 (24) | 6 (43) | |||
| MSI status‐no. (%) | |||||||||
| MSI‐high | 13 (48) | 7 (23) | .0548 | 2 (18) | 2 (9) | .81 | 0 | 0 | 1 |
| Non‐MSI‐high | 14 (52) | 24 (77) | 8 (73) | 17 (82) | 13 (100) | 14 (100) | |||
| NA | 0 | 0 | 1 (9) | 2 (9) | 0 | 0 | |||
| EBER‐no. (%) | |||||||||
| Positive | 6 (22) | 9 (29) | .2677 | 0 | 1 (5) | 1 | 0 | 1 (7) | 1 |
| Negative | 20 (74) | 17 (55) | 10 (91) | 18 (85) | 13 (100) | 13 (93) | |||
| NA | 1 (4) | 5 (16) | 1 (9) | 2 (10) | 0 | 0 | |||
| Prior line of therapy | |||||||||
| 0 | 11 (41) | 8 (26) | .5083 | 11 (100) | 20 (95) | 1 | 13 (100) | 13 (93) | 1 |
| 1 | 6 (22) | 9 (29) | 0 | 1 (5) | 0 | 1 (7) | |||
| 2 | 10 (37) | 14 (45) | 0 | 0 | 0 | 0 | |||
Note: Percentages may not total 100 because of rounding.
Abbreviations: NR, non‐responders; R, responders.